Targeted to the Gut. Designed for Local Action.

Plantibodies is developing proprietary plant-based technology and therapeutic products that enable oral delivery of biologics directly to the gastrointestinal tract.

Our approach is designed to deliver functional biologic medicines to the colon, where they can act locally with limited systemic exposure.

By integrating biologic production, protective bioencapsulation and targeted gastrointestinal delivery, Plantibodies is creating new opportunities for therapeutic innovation.

Proprietary technology. In vivo proof of concept. Industrial manufacturing capabilities. Pharmaceutical collaborations.

Addressing a Major Unmet Medical Need

Biologic medicines have transformed the treatment of serious diseases, including chronic gastrointestinal disorders. Yet many biologics are administered systemically, even when their intended therapeutic activity is located within the gastrointestinal tract.

For suitable therapeutic mechanisms, local oral delivery offers the potential to create differentiated medicines that combine biologic specificity with convenient administration and limited systemic exposure.

Plantibodies is focused on making this therapeutic approach possible.

GI-Restricted Delivery by Design

Most oral biologic delivery strategies aim to transport therapeutic proteins into the bloodstream.

Plantibodies takes a different approach.

Our technology is designed to deliver biologics directly to the gastrointestinal tract for localized therapeutic activity.

Rather than relying on systemic absorption, we focus on applications where gastrointestinal localization is the intended product characteristic.

This creates opportunities for a new category of locally acting oral biologic medicines.